Physician profile
Javier Morales
NPI 1508806712
$1,340,091.85
in general payments reported to CMS, 2019-2025
85 companies · $134K in 2025
The $134K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $279K · 2020: $168K · 2021: $179K · 2022: $219K · 2023: $199K · 2024: $163K · 2025: $134K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $305K · Consulting Fee: $107K · Travel and Lodging: $60K · Food and Beverage: $24K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $304,916.62 |
| Consulting Fee | $106,729.00 |
| Travel and Lodging | $60,281.08 |
| Food and Beverage | $23,671.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $466,401.43 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $415,798.83 | 2019-2025 | Ozempic, Victoza, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $135,270.44 | 2019-2025 | |
| Amgen INC. | $133,785.23 | 2019-2025 | Repatha, Repatha, Otezla |
| Eli Lilly and Company | $47,476.64 | 2019-2025 | Jardiance, Mounjaro |
| Novo Nordisk As | $38,981.82 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25,793.16 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Phathom Pharmaceuticals, INC. | $12,976.82 | 2024-2025 | Voquezna |
| Astrazeneca Pharmaceuticals Lp | $12,349.37 | 2019-2024 | Farxiga, Breztri |
| Sanofi-Aventis U.S. LLC | $8,640.16 | 2019-2024 | |
| Abbott Laboratories | $8,311.84 | 2020-2025 | Freestyle Libre 3 |
| Siemens Medical Solutions USA, INC. | $5,673.70 | 2025 | Atellica Im 1300 Analyzer |
| Idorsia Pharmaceuticals US INC | $3,618.88 | 2023-2025 | Tryvio, Quviviq |
| Mylan Specialty L.P. | $3,091.79 | 2019 | |
| Intuity Medical INC | $2,753.59 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
Show all 85 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Javier Morales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.